Secondary plasma cell leukemia in a patient with light chain multiple myeloma in post-chemotherapy remission phase
Dania Lizet Quintanilla-Flores, René Rodríguez‐Gutiérrez, Miguel Ángel Flores-Caballero
Abstract
Dania Lizet Quintanilla-Flores, René Rodríguez‐Gutiérrez, Miguel Ángel Flores-Caballero
Abstract
Plasma cell leukemia (PCL) is a rare presentation of multiple myeloma characterized by the presence of >20% plasma cells in peripheral blood, and an absolute plasma cell count >2 × 109 K/L. It is classified as primary and secondary with the latter representing a terminal event in 12% of patients. A case of a 78-year-old man who presented a secondary form of PCL during post-chemotherapy remission phase is discussed accompanied with a brief review.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Plasma cell leukemia (PCL) is a rare presentation of multiple myeloma characterized by the presence of >20% plasma cells in peripheral blood, and an absolute plasma cell count >2 × 109 K/L. It is classified as primary and secondary with the latter representing a terminal event in 12% of patients. A case of a 78-year-old man who presented a secondary form of PCL during post-chemotherapy remission phase is discussed accompanied with a brief review.
Key concepts: Plasma cell leukemia, Medicine, Multiple myeloma, Chemotherapy, Complete remission, Leukemia, Plasma cell, Peripheral blood